Anthropic announced that Novartis CEO Vas Narasimhan has joined its board of directors. The appointment signals the AI company's deepening commitment to healthcare and life sciences applications.
Narasimhan's addition to Anthropic's board comes as the Claude chatbot maker expands its presence in the pharmaceutical and biotech sectors. Earlier this month, Anthropic acquired biotech startup Coefficient Bio for approximately $400 million.
The move reflects growing interest from major healthcare companies in artificial intelligence capabilities. Narasimhan brings decades of experience in pharmaceutical leadership and drug development, positioning him to guide Anthropic's healthcare initiatives.
Anthhropic has been building specialized tools for life sciences research, leveraging Claude's language capabilities for tasks including drug discovery support and scientific analysis. The Coefficient Bio acquisition accelerated these efforts by bringing in specialized biotech expertise.
Board appointments from pharmaceutical executives represent a significant vote of confidence from the healthcare industry in Anthropic's technology and direction. The partnership may also facilitate future collaborations between Anthropic and Novartis on AI applications in drug development and healthcare.
Apple's latest desktop computers are built to support local artificial intelligence work, addressing the growing trend of developers using multiple Macs for AI tasks.
OpenAI's new Jalapeño chip outperforms Nvidia processors in inference benchmarks, delivering 1.5x-1.9x more AI work per watt and 1.7x-3.6x lower latency across multiple models.
Ukraine has granted British firms exclusive access to Avengers Labs, a platform containing roughly five million annotated battlefield images. The partnership marks the first international sharing of Ukraine's combat dataset for autonomous weapons development.